FcRn Antibody Binding to FcRn for Treating Autoimmune Diseases

• Main Authors: PARK SEUNG KOOK, KIM MIN SUN, SONG YEON JUNG, YONG HAE YOUNG, YOO TAE HYOUNG, JEONG JAE KAP, KIM EUN SUN, KIM SUNG WUK, AHN HYEA KYUNG, SHIN DONGOK
• Format: Patent
• Language: English; Korean
• Published: 20.12.2016
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; TESTING

본 발명은 IgG에 고친화성을 갖는 수용체인 FcRn(Neonatal Fc Receptor의 약자로, 태아 Fc-수용체, FcRP, FcRB 또는 Brambell 수용체라고도 불린다)에 특이적인 항체인 분리된 항-FcRn 항체, 이의 제조방법, 상기 항체를 포함하는 자가면역질환 치료용 조성물 및 상기 항체를 이용한 자가면역질환의 치료 및 진단 방법에 대한 것이다. 본 발명에 따른 FcRn 특이적 항체는 FcRn에 IgG와 비경합적으로 결합하여 혈중 내 병인성 자가항체의 양을 감소시킴으로써 자가면역질환(auto-immune disease)에 대한 치료에 활용 가능하다. The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.